Abstract Body

In the SMART trial, simultaneously stopping NRTIs and NNRTIs resulted in emergence of drug resistance mutations (DRMs) and lower HIV-RNA resuppression rates compared to either a PI-switch strategy or staggered discontinuation of the NNRTI before the NRTIs. This finding was proposed to be related to the longer half-life (T1/2) of NNRTIs compared to NRTIs, resulting in short-term NNRTI monotherapy. We postulated that since TDF has a long intracellular T1/2 (>60 hrs), stopping NNRTI-based ART containing TDF simultaneously may not result in lower resuppression rates or more resistance.

A reanalysis of the SMART study was undertaken in participants who interrupted NNRTI-based ART and later restarted an NNRTI regimen. Participants were included who had HIV-RNA<400 c/mL at ART discontinuation and had an HIV-RNA level drawn 4-8 months after restart to assess resuppression. For individuals who had HIV RNA >1000 c/mL at 2 months after ART interruption and had standard HIV genotypic testing (TRUGENE), presence of NNRTI or NRTI DRMs was assessed. Results are given according to stopping approach, separately for TDF vs. non-TDF use.

Of the 513 participants who met the inclusion criteria, 319 (62.2%) received EFV, and 194 (37.8%) received NVP. Stopping was simultaneous in 100 (19.5%) participants, staggered in 302 (58.9%), and switched in 111 (21.6%). Overall, 124 (24.2%) received TDF and 389 (75.8%) received other NRTIs (AZT, D4T, or ddI); in both groups the most common second NRTI was 3TC or FTC. Irrespective of TDF use, resuppression was lowest with simultaneous stopping and highest with a switch strategy (Table). Among those who stopped simultaneously, there was no difference between TDF or non-TDF group for rate of resuppression (95% CI for difference: -26.3, 8.2; p=0.27) or percent with NNRTI DRM (95% CI for difference: -0.9, 34.3; p=0.20). Results were similar for those stopping EFV and NVP (data not shown).

Despite TDF having a longer intracellular T1/2 than other NRTIs, the resuppression rate after simultaneously stopping all ARVs in an NNRTI-regimen was not different for TDF versus non-TDF regimens, nor did TDF prevent emergence of DRMs. Though limited by small number of subjects on TDF, these data support the current recommendation that if stoppage of an NNRTI-based regimen is planned, ARVs should not be stopped simultaneously. This is particularly crucial when stopping NNRTI regimens during analytical ART interruption trials.